Cancer Research

Human CD271-Positive Melanoma Stem Cells Associated with Metastasis Establish Tumor Heterogeneity and Long-term Growth

Gianluca Civenni[1], Anne Walter[3], Nikita Kobert[4], Daniela Mihic-Probst[5], Marie Zipser[4], Benedetta Belloni[4], Burkhardt Seifert[2], Holger Moch[5], Reinhard Dummer[4], Maries van den Broek[3], and Lukas Sommer[1]

Abstract

Human melanoma is composed of distinct cell types reminiscent of neural crest derivatives and contains multipotent cells that express the neural crest stem cell markers CD271(p75^{NTR}) and Sox10. When isolated from solid tumors by using a method that leaves intact cell surface epitopes, CD271-positive, but not CD271-negative, cells formed tumors on transplantation into nude or nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice. These tumors fully mirrored the heterogeneity of the parental melanoma and could be passaged more than 5 times. In contrast, in more immunocompromised NOD/SCID/IL2rγ^{null} mice, or in natural killer cell–depleted nude or NOD/SCID mice, both CD271-positive and CD271-negative tumor cell fractions established tumors. However, tumors resulting from either fraction did not phenocopy the parental tumors, and tumors derived from the CD271-negative cell fraction could not be passaged multiple times. Together, our findings identify CD271-positive cells as melanoma stem cells. Our observation that a relatively high frequency of CD271/Sox10-positive cells correlates with higher metastatic potential and worse prognosis further supports that CD271-positive cells within human melanoma represent genuine cancer stem cells. *Cancer Res; 71(8); 3098–109. ©2011 AACR.*

Downloaded from http://aacrjournals.org/cancerres/article-pdf/71/8/3098/2661525/3098.pdf by guest on 29 April 2025

Introduction

Tumors usually are heterogenic and comprise cells with different capacities to proliferate and differentiate. It has been proposed that this cellular heterogeneity depends on the presence of so-called cancer stem cells, which are defined as cells that can induce *de novo* tumor formation, self-renew *in vivo*, and reestablish the cellular composition of the parental tumor (1). Although the cancer stem cell concept is accepted for several types of tumors (2), data for human melanoma, the most aggressive skin cancer, are conflicting (3). For example, melanoma cells exhibiting stem cell properties *in vitro* displayed increased tumorigenicity as compared with melanoma cells lacking self-renewal potential on xenotransplantation into immunodeficient nude or nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice (4). Later studies suggested that the expression of markers such as CD20, CD133, and MDR1 are associated with melanoma stem cells (4–6), but a strict correlation between marker expression, self-renewal *in vitro* and *in vivo*, multilineage differentiation, and high tumorigenicity remains to be established (7). More recently, ABCB5 has been identified as a marker of melanoma-initiating cells capable of self-renewal and differentiation and associated with clinical melanoma progression in human patients (8). Similarly, in fully immunocompromised mouse models, including NOD/SCID/IL2rγ^{null} (NSG) mice, melanoma cells expressing the neurotrophin receptor CD271 (p75^{NTR}) had a higher tumor-initiation capacity than CD271-negative cells, although the negative fraction was also able to generate tumors in these mouse models (9).

In contrast, other recent studies reported a generally high frequency of tumorigenic melanoma cells when NSG mice were used as recipients (10, 11). In addition, these studies did not find a correlation between the capacity to form a tumor and the expression of previously published markers, including CD271 and ABCB5, thus questioning the concept of cancer stem cells (10, 11).

Because cancer stem cells by definition must be able to reproduce the full heterogeneity of the parental tumor and to grow continuously even after multiple passages, we embarked to compare those aspects for the tumors arising in NOD/SCID, nude, and NSG mice after transplantation of CD271-positive versus -negative melanoma cell fractions. To this end, the cells were isolated from human melanoma samples applying an enzymatic tumor digestion protocol that does not harm surface epitopes. Using this gentle method of cell fraction preparation, we reveal that CD271-positive melanoma cells meet

Authors' Affiliations: [1]Cell and Developmental Biology, Institute of Anatomy and [2]Biostatistics Unit ISPM, University of Zurich; Departments of [3]Oncology, [4]Dermatology, and [5]Pathology, Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland

Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

Corresponding Author: Lukas Sommer, University of Zurich, Winterthurerstrasse 190, Zurich 8057, Switzerland. Phone: 41-44-6355350; Fax: 41-44-6356895; E-mail: lukas.sommer@anatom.uzh.ch

doi: 10.1158/0008-5472.CAN-10-3997

©2011 American Association for Cancer Research.

AACR American Association for Cancer Research

the definition of melanoma stem cells. Intriguingly, the incidence of such cells in patient biopsies is associated with poor prognosis.

Materials and Methods

Tissue microarray analysis

All analyses involving human melanoma tissue were carried out in accordance with the ethical committee in canton Zurich. The tissue microarray used here comprised 54 primary melanomas, 141 melanoma metastases, and 53 melanoma cell lines and was generated as described (12, 13). Coexpression of CD271 and Sox10 was identified by double immunostaining (Sox10, 1:800, R&D, MBA2864; CD271, 1:50, Miltenyi Biotec, 130-091-883). The staining procedure was done as previously described (12). The frequency of cells that express CD271 plus Sox10 is presented as mean ± SD and median with interquartile range (IQR). Values were compared by using the Mann–Whitney *U* test with exact *P* values. Tumor-specific survival was analyzed by using Kaplan–Meier curves and compared between groups by log-rank test. SPSS 15 software (SPSS Inc.) was used for statistical analyses. Two-tailed *P* values of 0.05 or less were considered statistically significant.

Mice

BALB/c-Swiss nude (CAnN.Cg-*Foxn1*^{nu}/Crl, Nude) and NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/S, NSG) mice were purchased from Charles River. NOD/SCID (NOD.CB17/JHliHsd-*Prkdc*^{scid}, N/S) mice were obtained from Harlan Laboratories. Mice were housed under standard conditions with free access to water and food. Experiments were carried out with male or female mice of 6 to 10 weeks of age in accordance with the Swiss federal and cantonal laws on animal protection.

Tumor cell isolation and xenotransplantation

All patients enrolled in the study were treated at the Dermatology Department of the University Hospital of Zurich. The study was approved by the ethics committee of canton Zurich and all patients gave informed consent. Immediately after surgical resection, the solid, metastatic lesions were dissociated into single-cell suspensions by using Hank's buffered salt solution (without Ca^{2+} and Mg^{2+}; Invitrogen) containing collagenase III (1 mg/mL; Worthington Biochem) and dispase (0.5 mg/mL; Roche). Incubation at 37°C for 1 hour with concurrent mincing allowed complete digestion. In some cases, xenografts and cell lines were dissociated as indicated earlier in the text, followed by an additional digestion with trypsin (0.05% trypsin-EGTA; Gibco) for 5 minutes at 37°C, exactly as described (10, 11). The resulting cell suspension was filtered through 40-μm nylon mesh and single cells were harvested. Tumor xenografts (1 cm^2) were harvested from euthanized mice and dissociated as described earlier in the text. A 1,000-bulk tumor, either *in vitro* cultured or as fluorescence-activated cell sorting (FACS)-sorted cells, was resuspended in Matrigel matrix (BD Biosciences) 1:1 diluted with RPMI-1640 (Invitrogen), and 200 μL were injected s.c. in the flank of mice with a 1-mL syringe with a 25-gauge hypodermic needle.

Immunofluorescence

Paraffin-embedded, 4-μm formalin fixed tissue sections were deparaffinized in xylene and rehydrated. Following heat-induced epitope retrieval by using 10 mmol/L trisodium citrate buffer at pH 6.0 and a Microwave Histoprocessor (Milestone), the sections were incubated overnight at 4°C as described with antibodies for the following markers: Sox10 (1:800; R&D, MAB2864), CD271 (1:200; Alomone Labs, ANT-007), MelanA (1:50; Abcam, Ab785), S100P (1:400; DAKO, Z0611), HMB45 (1:100; DAKO, M0634), microphthalmia-associated transcription factor (MITF; 1:100; Acris, DM4625), neuron-specific class III beta-tubulin (TuJ1; 1:200; Sigma, T8660), neurofilament 160 (NF; 1:200; Sigma, N5264), neuron-specific enolase (NSE; 1:100; Abcam, Ab53025), Peripherin (1:100; Abcam, ab4666), smooth muscle actin (SMA; 1:400; Sigma, A2547), and green fluorescent protein (GFP; 1:500; Abcam, Ab290). Sections were subsequently incubated with following secondary antibodies for 1 hour at room temperature: Cy3-conjugated goat antimouse (1:500; Jackson ImmunoResearch Laboratories), Cy3-conjugated goat antirabbit (1:500; Jackson ImmunoResearch Laboratories), Alexa 488-conjugated goat antimouse (1:500; Invitrogen). All slides were counterstained with Hoechst 33342 (Invitrogen). In addition, sections were stained with hematoxylin and eosin (H&E). Stainings on cultured cells were done as described (14).

Quantification of positive cells was done by ImageJ software (NIH). Three images from each biopsy were taken randomly. Images were imported into ImageJ, converted to 8-bit formats, and subjected to automatic threshold. The "Analyze Particles" function was used to count positive cells.

Flow cytometry and FACS

All steps for flow cytometry were carried out in RPMI-1640 supplemented with 10% fetal calf serum (Invitrogen), 5% Pen/Strep (Invitrogen), and 2 mmol/L EDTA. For sorting or analysis, single cell tumor samples were stained with antihuman CD271 (Miltenyi Biotec; FITC-conjugated: 130-091-917, or APC-conjugated: 130-091-884), antihuman CD44 (1:100; BD Pharmingen, 555477), or anti-ABCB5 antibody (1:200; clone 3C2-1D12, a gift from Markus Frank). Samples were measured with FACScanto II (BD Biosciences) and analyzed with Diva software (BD Biosciences). Sorting was done with FACSAria (BD Biosciences), and the purity of sorted fractions was 95% to 99% of CD271-positive cells in the CD271-enriched fraction and less than 0.5% of CD271-positive cells in the CD271-depleted fraction.

Natural killer cell depletion

Mice were injected i.p. with 50 μL polyclonal rabbit anti-asialo GM1 antibodies (Wako Chemicals, catalogue no. 986-10001) in 150 μL PBS every 5 days starting at the day of melanoma cell engraftment, which resulted in a greater than 95% depletion of $CD3^{-}$ $DX5^{+}$ natural killer (NK) cells for the duration of the experiment as measured by flow cytometry (15).

Sphere culture

Sphere cultures were established as previously described for neural stem cells (16). Briefly, single cells were plated in flasks

Downloaded from http://aacrjournals.org/cancerres/article-pdf/71/8/3098/2661525/3098.pdf by guest on 29 April 2025

(Nunc) coated with Poly(2-hydroxyethylmethacrylate) (Poly-Hema; Sigma) at a density of 20,000 viable cells/mL in DMEM-F12 1:1 media (Gibco) containing 1× B-27 supplement (Invitrogen), 20 ng/mL FGF2 (PeproTech), 10 ng/mL EGF (PeproTech), and 5% Pen/Strep (Invitrogen). The resulting spheres were collected after 7 to 10 days by gentle centrifugation (800 rpm), dissociated by using PBS containing 2 mmol/L EDTA, and replated into Poly-Hema–coated culture flasks. To ensure plating of single, viable cells, the dissociated sphere cells were passed through a 40 μm nylon mesh followed by Trypan blue examination. To assess the relative sphere numbers over passage, spheres were grown for 7 days, counted, dissociated, and replated under the same conditions.

Melanoma cell lines

Cell lines M990115 and M010817 were previously described (17). The cell line M070302 was established from surplus material from a xenograft (patient 2481) generated in nude mice. Cell lines were grown in sphere culture condition as describe earlier in the text.

Transduction of melanoma with GFP-expressing lentivirus

The GFP-expressing lentivirus was produced as described (18). Lentivirus-containing supernatants were collected 48 hours after transfection, filtered through a 0.22-μm membrane, and transferred to target cells (see the following text). We xenografted a fresh human melanoma into nude mice, processed the xenograft into single cells and cultured them under sphere conditions. Cells were transduced with GFP-lentivirus at the eighth passage. After 1 week, resulting GFP-tagged cells were checked by FACS and injected s.c. into nude mice. The GFP-tagged xenografts were collected after 2 months, dissociated into single cells, and GFP-positive cells were purified by FACS sorting.

Generation of GFP-tagged clones

After *in vitro* transduction, GPF-expressing cells were stained for CD271 and single-cell sorting was done on a BD FACSAria sorting system. Fibronectin-coated (Sigma) 96-well flat-bottom tissue culture plates (Nunc) were used for 1 cell per well sorting into 200 μL of medium (RPMI-1640 supplemented with 10% FCS, 2 mmol/L glutamine, 5% Pen/Strep) per well. Each well was checked with a fluorescence microscope, and only wells containing a single cell were processed further. After 2 weeks in culture, clones were stained for CD271 expression and 3 selected clones were processed as follows. The clone was divided into 2 aliquots; 1 aliquot was cultured for 4 hours fixed, and stained for different markers as described earlier in the text, and the other aliquot was xenografted into nude and NSG mice.

Results

Xenotransplantation into highly immunocompromised mouse models fails to phenocopy the cellular heterogeneity of parental human melanoma samples

Because melanoma derives from the neural crest cell lineage, we expect putative melanoma stem cells to exhibit features of neural crest stem cells (NCSC) and individual tumors to comprise cells expressing the NCSC markers CD271 and Sox10 (19, 20) as well as cells with features of different neural crest derivatives. To examine the cellular heterogeneity of a given patient's tumor, we analyzed 19 independent melanoma metastases (Supplementary Table S1) for the expression of 11 NCSC, melanocytic, neural, and mesenchymal markers and found that the majority of the samples were positive for most or all of these markers (Fig. 1A and B; Supplementary Fig. S1).

To investigate mechanisms of human melanoma formation and propagation, it is imperative to use a model that faithfully reproduces the parental phenotype, which we will call phenocopy hereafter. Melanoma cell xenotransplantation into different models of immunodeficient mice, including highly immunocompromised NSG mice, previously led to conflicting results (3, 7). To address which mouse model(s) for melanoma formation might best recapitulate the cellular composition of parental tumors, 1,000 cells from the bulk of various patient samples were injected s.c. into nude, NOD/SCID, and NSG mice, and sections of the resulting xenografts were stained for the expression of 11 markers. The transplanted bulk melanoma cells gave rise to tumors in all cases. Importantly, 100% of all xenografts in nude and NOD/SCID mice were exact phenocopies of the parental tumors with respect to the presence of all markers tested (Fig. 1; Supplementary Fig. S2; Table 1). In contrast, all xenografts in NSG mice ($n = 7$) differed from the parental tumors and lacked cells expressing one or more of the following markers: CD271, MITF, S100P, and neuronal markers (Fig. 1; Supplementary Fig. S2; Table 1). Quantification of cells expressing a given marker confirmed the consistency of CD271/Sox10, S100P, and MITF expression between nude and NOD/SCID xenografts and the respective parental tumors, and the discrepancies in marker expression between NSG xenografts and original patient tumors (Fig. 1C).

Because the major difference between NSG mice and nude or NOD/SCID mice is the absence of NK cells in NSG mice, we addressed whether NK cells influence the phenotype of xenografted tumors by depleting NK cells from nude and NOD/SCID mice (15). Intriguingly, xenotransplanted melanoma cells did not phenocopy the parental tumor in NK-depleted NOD/SCID mice (Fig. 1A–C; Supplementary Fig. S3; Table 1). Thus, the level of immunocompetence of the xenotransplant recipient crucially affects the capacity of human melanoma cells to form tumors resembling the respective patient melanoma.

CD271-positive melanoma cells are multipotent and able to establish the heterogeneity of the parental tumor

It has recently been debated whether CD271-positive melanoma cells isolated from patient tumors possess an increased tumorigenic capacity in fully immunocompromised mice as compared with CD271-negative cells (9–11). Notably, in these conflicting reports and other studies, different enzymatic procedures have been used to prepare cell fractions from solid melanoma samples. Tumors have been mechanically

Downloaded from http://aacrjournals.org/cancerres/article-pdf/71/8/3098/2661525/3098.pdf by guest on 29 April 2025



B Marker expression rate in human melanoma biopsies

Marker	Frequency
CD271/Sox10	19/19
MelanA	16/19
S100P	19/19
HMB45	15/19
MITF	17/19
TuJ1	15/19
NF	15/19
NSE	15/19
Peripherin	14/19
SMA	19/19

C Quantification of marker expression in human biopsies and xenografts

Marker		% of cells positive for given marker (± SD)			
	Patient ID	Patient	N/S	NSG	N/S_GM1
CD271/Sox10	31651	15 ± 2	10 ± 3	0	30 ± 5
	3298	8 ± 4	10 ± 2	12 ± 1	9 ± 5
S100P	31651	86 ± 7	20 ± 4	42 ± 5	53 ± 5
	3298	65 ± 10	72 ± 12	50 ± 13	0
MITF	31651	91 ± 11	83 ± 5	0	0
	3298	89 ± 5	79 ± 5	36 ± 8	0

Figure 1. Xenografted melanoma phenocopy the parental tumor in NOD/SCID mice, but not in NSG or NK-depleted NOD/SCID mice. A, immunofluorescent staining of 2 original human melanoma tissues (patients 31651 and 3298) and corresponding xenografts in NOD/SCID (N/S), NSG, and NK-depleted NOD/SCID (N/S_GM1) mice for the NCSC-specific markers CD271 (red) and Sox10 (green; white arrows, insets) and the differentiation markers MelanA, S100P, HMB45, MITF, TuJ1, NF, NSE, Peripherin, and SMA (in green). Tissues were counterstained with Hoechst 33342. Expression or absence of a given marker is labeled by + or −, respectively. Bottom, tissues after staining with H&E. Scale bar, 100 µm. B, incidence of 11 tested markers in 19 independent human metastatic melanoma lesions. C, frequency of cells expressing CD271/Sox10, S100P, and MITF in 2 human metastatic melanoma tissues (patients 31651 and 3298) and in corresponding xenografts in N/S, NSG, and N/S_GM1 mice. Values are presented as mean ± SD.

dissociated followed by enzymatic digestion with collagenase (8), a mix of collagenase and dispase (9), or collagenase and trypsin (10, 11, 21). Therefore, we addressed whether these different tumor digestion protocols might affect detectability of surface markers used to directly isolate putative tumorigenic melanoma cell populations. Strikingly, the percentage of retrievable CD271- and ABCB5-positive cells was consistently reduced in conditions that included a trypsin incubation step (11), whereas CD44 was not affected (Supplementary Fig. S4). These results show that a strong proteolytic activity can selectively damage surface protein epitopes and thus lead to reduced detectability by the corresponding antibodies. This unavoidably results in underestimation of surface marker expression in human melanoma cells and in negative fractions being contaminated by cells actually expressing the selected marker. For this reason, in this study human biopsies and xenografts were dissociated in the absence of trypsin activity.

Using this gentle protocol for tumor dissociation and cell isolation, FACS-sorted CD271-positive melanoma cells from primary xenografts consistently promoted tumor formation in nude and NOD/SCID mice, whereas the CD271-negative cell fraction never gave rise to tumors (Fig. 2A; 32 transplantations representing 7 distinct patient tumors). In contrast, we did not detect differences in tumor initiation in NSG mice between CD271-positive and CD271-negative cells from primary xenografts (12 transplantations each, representing 3 distinct

Downloaded from http://aacrjournals.org/cancerres/article-pdf/71/8/3098/2661525/3098.pdf by guest on 29 April 2025

Table 1. Phenocopy of the parental tumors by grafted bulk melanoma cells

Marker	% of xenografts phenocopying patient tumors (*n*)			
	Nude	N/S	NSG	N/S_GM1
CD271/Sox10	100 (3)	100 (7)	71 (7)	100 (4)
S100P	100 (3)	100 (7)	71 (7)	80 (4)
HMB45	100 (3)	100 (7)	100 (7)	20 (4)
MITF	100 (3)	100 (7)	57 (7)	20 (4)
Tuj1	100 (3)	100 (7)	86 (7)	60 (4)
NF	100 (3)	100 (7)	86 (7)	60 (4)
NSE	100 (3)	100 (7)	71 (7)	80 (4)
Peripherin	100 (3)	100 (7)	57 (7)	40 (4)
All markers	100 (3)	100 (7)	0 (7)	0 (4)

NOTE: Capacity of unsorted melanoma cells to generate phenocopies of parental tumors in different mouse hosts. Xenografts were generated in nude, N/S, NSG, and N/S mice treated with anti-asialo GM1 antibodies. Values represent the percentage of xenografts that phenocopy the parental tumor with respect to expression of the indicated marker.

patient tumors; Fig. 2A). Strikingly, in NK-depleted nude or NOD/SCID mice both CD271-positive and CD271-negative cells initiated tumor formation. Hence, the tumorigenic potential of melanoma cell subpopulations is influenced by the presence of NK cells in xenograft recipients.

Because a cancer stem cell by definition must display the differentiation capacity reflecting its parental tumor, we investigated the heterogeneity of different successfully xenografted tumors in NOD/SCID, nude, and NSG mice and of the corresponding parental tumor. The cellular composition of all nude and NOD/SCID xenografts derived from CD271-positive cells (tumors representing 7 distinct patients) was analogous to the corresponding parental tumors (Fig. 2B; Supplementary Fig. S5). In contrast, in NSG mice neither CD271-positive nor CD271-negative cells were able to fully phenocopy the cellular heterogeneity of the corresponding parental tumors with respect to all 11 markers tested (Fig. 2B; Supplementary Fig. S5; Table 2). Of importance, both the CD271-positive and -negative cell fractions failed to consistently generate xenografts expressing crucial melanoma markers such as MITF and S100P or neuronal markers present in the parental tumors. Moreover, none of the tumors produced by CD271-negative cells in NSG mice comprised CD271-positive cells, despite the presence of such cells in the parental tumors (Fig. 2B; Supplementary Fig. S5; Table 2; 12 transplantations representing 3 patients' tumors). In summary, faithful phenocopies of original patient tumors were only achieved on transplantation of CD271-positive melanoma cells into nude and NOD/SCID mice, but not into NSG mice.

The fact that CD271-positive cells generate the full heterogeneity of human melanoma on xenotransplantation into NOD/SCID or nude mice suggests that these cells are multipotent. To specifically address this issue, we infected melanoma cells from a xenograft of patient sample 2481 with a GFP-expressing lentivirus, followed by FACS of GFP/CD271 double-positive cells and plating of those cells at clonal density. Although 19 ± 4% of the CD271-positive cells gave rise to clones consisting of more than 10 cells after 2 weeks in culture, such clones were not observed in the CD271-negative cell fraction (Fig. 2C). Three clones derived from GFP/CD271 double-positive founder cells were selected and subjected to differentiation assays in cell culture, revealing the emergence of multiple cell types, such as cells expressing CD271/Sox10, neuronal and melanocytic markers, and SMA (Fig. 2D). Thus, the CD271-positive melanoma cell fraction contains a population that is clonogenic and multipotent in cell culture, similar to NCSCs.

To address the multipotency of CD271-positive melanoma cells *in vivo*, cells from the 3 selected clones were grafted s.c. into nude and NSG mice, and the xenografts were analyzed for expression of the 11 markers as described before. In nude mice, the 3 clones were able to establish a cellular hierarchy with all 11 markers present in the xenografts. In particular, 10.2 ± 2.0% of the xenograft cells derived from a CD271-positive cell expressed CD271. Moreover, although most smooth muscle cells present in the xenografts were host derived, all nude xenografts comprised cells double positive for SMA and GFP, revealing that some smooth muscle cells in the tumor originated from CD271-positive melanoma cells. In contrast, neither the NCSC markers CD271/Sox10 nor S100P, MITF, and neuronal traits were consistently expressed in xenografts derived from clones transplanted into NSG mice. Moreover, we did not find any GFP/SMA double-positive cells in the NSG grafts, suggesting that the NSG host environment either suppresses the *in vivo* multipotency of CD271-positive cells or supports the growth of melanoma cells with restricted developmental capacities (Fig. 2D; Supplementary Fig. S6).

CD271-positive melanoma cells have self-renewal capacity and sustain long-term tumor growth *in vivo*

To address whether CD271-positive cells have self-renewal capacity, in addition to being multipotent (Fig. 2B–D), we

Downloaded from http://aacrjournals.org/cancerres/article-pdf/71/8/3098/2661525/3098.pdf by guest on 29 April 2025



Figure 2. Xenografted CD271-positive melanoma cells phenocopy the parental tumor in nude mice, but not in NSG mice. A, the efficiency of tumor formation for independently xenografted CD271-positive or CD271-negative melanoma cells in nude, N/S, NSG, and NK-depleted NOD/SCID (N/S_GM1) mice. The numbers represent the number of growing xenografts, and the values in parentheses represent the total number of transplantations/the number of independent patient samples. B, immunofluorescent staining of a representative original human melanoma tissue (patient 2481) and corresponding xenografts after injection of CD271-positive or CD271-negative in nude or NSG mice for the NCSC-specific markers CD271 (red) and Sox10 (green; white arrows, insets) and the differentiation markers MelanA, S100P, HMB45, MITF, TuJ1, NF, NSE, Peripherin, and SMA (in green). Tissues were counterstained with Hoechst 33342. Expression or absence of a given marker is labeled by + or −, respectively. Scale bar, 100 μm. C, melanoma cells from a xenograft (nude) of patient sample 2481 were infected with a GFP-expressing lentivirus, and FACS-sorted GFP+/CD271+ or GFP+/CD271− cells were plated at clonal density. Plating efficiency was 56 ± 6% for CD271-positive and 69 ± 7% for CD271-negative cells. Clones generated by CD271+ (white bars) and CD271− (black bars) cells were evaluated after 2 weeks of culture under adherent culture conditions. Values are presented as mean ± SD. D, a clone derived from GFP+/CD271+ cell was cultured, revealing the emergence of multiple cell types, such as cells expressing CD271/Sox10, neuronal and melanocytic markers, and SMA (Fig. 3D, left; scale bar 100 μm). In addition, part of the clone was xenografted into nude and NSG mice, and tumors were stained for GFP (green) and the markers described earlier (red; middle and right; scale bar, 50 μm). Data from 1 representative clone out of 3 are shown.

carried out sphere assays under conditions that are known to support sphere formation and self-renewal of normal skin-derived NCSCs (16). CD271-positive cells isolated from fresh melanoma tissue or from melanoma cell lines readily generated spheres that contained CD271/Sox10-positive cells and that could be propagated by serial passaging, whereas the few spheroid aggregates generated by the CD271-depleted melanoma cell fraction displayed a reduced passaging capacity

Downloaded from http://aacrjournals.org/cancerres/article-pdf/71/8/3098/2661525/3098.pdf by guest on 29 April 2025

Table 2. Phenocopy of the parental tumors by CD271-positive melanoma cells

Marker	% of xenografts phenocopying patient tumors (*n*)		
	Nude CD271$^+$	NSG CD271$^+$	NSG CD271$^-$
CD271/Sox10	100 (4)	100 (2)	0 (3)
S100P	100 (4)	0 (2)	66 (3)
HMB45	100 (4)	100 (2)	100 (3)
MITF	100 (4)	0 (2)	0 (3)
Tuj1	100 (4)	0 (2)	0 (3)
NF	100 (4)	100 (2)	100 (3)
NSE	100 (4)	100 (2)	100 (3)
Peripherin	100 (4)	100 (2)	33 (3)
All markers	100 (4)	0 (2)	0 (3)

NOTE: Capacity of CD271-positive versus CD271-negative melanoma cell fractions to generate phenocopies of parental tumors in nude or NSG Mice. Values represent the percentage of xenografts generated by CD271-positive (CD271$^+$) or CD271-negative (CD271$^-$) cells that phenocopy the parental tumor with respect to expression of the indicated marker.

(Fig. 3A and B). Determining the ratio between numbers of secondary over primary and quinternary over quaternary spheres showed that CD271-positive, but not CD271-negative, cells have an extensive self-renewal potential and expand their stem cell activity over time (Fig. 3B).

To confirm the self-renewal potential of CD271-positive melanoma cells *in vivo*, we isolated CD271-positive and CD271-negative cells from primary xenografts generated by bulk tumor cells in nude mice and retransplanted these cell fractions. We found that only CD271-positive cells were able to generate secondary tumors in nude mice (Fig. 3C and D; Supplementary Fig. S7, "first passage"; $n = 4$ for each biopsy). Likewise, CD271-positive cells reisolated from secondary xenografts consistently generated tertiary tumors, unlike CD271-negative cells (Fig. 3C and D; Supplementary Fig. S7, "second passage"). To test whether the cellular heterogeneity originating from CD271-positive cells is a stable trait *in vivo*, we analyzed first and second passage xenografts by immunofluorescence. Intriguingly, not only the cellular heterogeneity with respect to neural crest-specific differentiation markers (Fig. 3D; Supplementary Fig. S7) but also the frequency of CD271-positive cells was maintained in xenografts directly generated from unsegregated patients' melanoma cells and in tumors obtained by serial *in vivo* passaging of CD271-positive cells (Fig. 3C; percentage of CD271-positive cells in primary xenograft, first passage, and second passage, respectively: 10 $\pm$ 1%, 11 $\pm$ 3%, 8 $\pm$ 2%; $n = 4$). Hence, CD271-positive melanoma stem cells faithfully phenocopy the parental tumor in nude mice, even after multiple passages *in vivo*.

Our data suggest that the presence of CD271-expressing melanoma stem cells is a prerequisite for long-term tumor propagation. Therefore, although CD271-negative melanoma cells can generate tumors in NSG, NK-depleted NOD/SCID, or NK-depleted nude mice (Fig. 2; refs. 9, 10), we expected that such tumors could not be maintained *in vivo* over a prolonged time period. To test this, we serially passaged tumors generated in NSG mice from CD271-positive or CD271-negative cells, using tumors produced by CD271-positive melanoma cells in nude mice as positive control. In both nude and NSG mice, tumors originating from CD271-positive cells allowed propagation *in vivo* over 5 passages, in accordance with the earlier-described *in vivo* self-renewal capacity of CD271-positive cells in nude mice (Fig. 4). In striking contrast, tumors derived from CD271-negative cells in NSG mice exhausted with time and could only be propagated *in vivo* for 3 to 4 passages (Fig. 4). Quantification of CD271-expressing cells in consecutively produced NSG xenografts revealed that the capacity for tumor propagation over several passages was associated with the presence of CD271-positive melanoma stem cells in each xenograft (Fig. 4A–C). CD271-negative cells, however, were unable to produce CD271-positive cells, even after xenograft passaging (Fig. 4A and D). It should be noted, however, that although CD271-positive cells generate tumors in NSG mice that can be serially passaged, those tumors did not phenocopy the parental tumor (Fig. 2).

Thus, NSG mice, NK-depleted NOD/SCID mice, or NK-depleted nude mice provided a host environment permissive for tumor growth by CD271-negative cells, whereas such cells were unable to initiate tumorigenesis in NOD/SCID or nude mice. In contrast, CD271-positive melanoma stem cells were tumorigenic in all mouse models tested. In any case, only in nude or NOD/SCID mice CD271-positive melanoma stem cells produced tumors that completely phenocopied the parental melanoma even on serial xenotransplantation, whereas they failed to do so in NSG mice.

Expression of the NCSC markers CD271/Sox10 correlates with metastatic potential and poor prognosis of melanoma

To verify our findings with a large number of patient samples, we stained tissue microarrays containing more than 200 different melanoma biopsies of primary melanomas,

Downloaded from http://aacrjournals.org/cancerres/article-pdf/71/8/3098/2661525/3098.pdf by guest on 29 April 2025



Figure 3. CD271-positive melanoma cells have the capacity of self-renewal *in vitro* and *in vivo*, in contrast to CD271-negative melanoma cells. A, light microscopy (left) of a representative human melanoma sphere and immunofluorescent staining (right) for CD271 (red) and Sox10 (green; white arrow, inset). Scale bar, 50 μm. B, propagation of CD271$^+$-derived (white bars) and CD271$^-$-derived (black bars) spheres by serial passaging. Spheres were obtained from melanoma cell lines (M990115 and M010817; ref. 17), and metastatic melanoma lesions (824 and 4286). The data (mean ± SD, $n = 4$) are given as ratios of second/first passage and fifth/fourth passage, respectively. C, number of CD271-positive cells (mean ± SD) in primary xenografts obtained by direct transplantation of patients' tumor material ($n = 4$), in secondary tumors derived from CD271-positive cells selected from primary xenografts ($n = 4$; first passage), and in tertiary tumors derived from CD271-positive cells selected from secondary tumors ($n = 4$; second passage). D, human melanoma (patient 4286) and corresponding primary and secondary xenografts derived in nude mice from CD271-positive cell fractions were stained for the NCSC markers CD271 (red) and Sox10 (green; white arrows, insets) and the differentiation markers MelanA, S100P, HMB45, MITF, TuJ1, NF, NSE, Peripherin, and SMA (in green). Tissues were counterstained with Hoechst 33342. Expression or absence of a given marker is labeled by + or −, respectively. Bottom, tissues were stained with H&E. Scale bar, 100 μm.

melanoma metastases, and melanoma cell lines for cells coexpressing the NCSC transcription factor Sox10 (20) and CD271 that is found both in NCSCs (16, 19) and in melanoma-initiating cells (9). Consistent with its expression in NCSCs and melanocytes, nuclear Sox10 was found in the majority of cells in melanoma cell lines, primary melanomas, and

Downloaded from http://aacrjournals.org/cancerres/article-pdf/71/8/3098/2661525/3098.pdf by guest on 29 April 2025



A Long-term growth of tumors containing CD271-positive cells

Mouse strain	CD271 fraction	P1 Tumor formation	P1 CD271 % ± SD	P2 Tumor formation	P2 CD271 % ± SD	P3 Tumor formation	P3 CD271 % ± SD	P4 Tumor formation	P4 CD271 % ± SD	P5 Tumor formation	P5 CD271 % ± SD
Nude	+	8(8/2)	7.0 ± 2.8	8(8/2)	10.4 ± 2.7	8(8/2)	10.1 ± 2.8	8(8/2)	6.4 ± 1.5	8(8/2)	7.5 ± 1.4
	-	0(8/2)									
NSG	+	4(4/1)	4.1 ± 1.0	4(4/1)	4.6 ± 0.7	4(4/1)	6.6 ± 0.8	4(4/1)	5.9 ± 1.8	4(4/1)	5.9 ± 3.2
	-	8(8/2)	0	8(8/2)	0	4(8/2)	0	0(4/2)			

Figure 4. Capacity of CD271-positive cells to sustain long-term tumor growth. A, sorted cells from 2 melanoma biopsies (patients 2481 and 10477) were used to generate tumors (passage P1). From passage P2 to passage P5, cells were injected into mice as whole-tumor single-cell suspensions. A total of 1,000 cells from each fraction were injected s.c. The numbers represent the number of growing xenografts, the values in parentheses represent the total number of transplantations/the number of independent patient samples. CD271 expression levels were measured by FACS and are expressed as mean ± SD ($n = 4$). B and C, representative flow cytometry analysis of human melanoma xenografts (patient 2481) generated by CD271-positive cells (passage P1) and by bulk cells (passages P2 and P3) in nude (B) or NSG (C) mice. D, representative flow cytometry analysis of human melanoma xenografts (patient 2481) generated by CD271-negative cells (passage P1) and by bulk cells (passages P2 and P3) in NSG mice. CD271 signal was plotted against the side scatter (SSC-H).

metastases (Fig. 5A). In contrast, the number of cells with detectable CD271 expression was highly variable. Among primary melanoma biopsies, we found 31 biopsies without detectable CD271 expression (57%), 14 biopsies with less than 5% CD271-positive cells (26%), and 9 biopsies with more than 5% of CD271-positive cells (17%). Intriguingly, however, the proportion of CD271/Sox10 double-positive cells in primary tumors without evidence of metastasis was significantly less than that in primary tumors of patients, who developed metastases during 5-year follow-up ($P = 0.01$; Fig. 5B). In addition, there was a higher proportion of CD271/Sox10-positive cells in metastases as compared with primary tumors without evidence of metastasis ($P = 0.04$, Fig. 5C). Similarly, the proportion of CD271/Sox10-positive cells was significantly increased in cell lines derived from metastases as compared with cell lines derived from primary tumors ($P = 0.01$; Fig. 5C). Thus, both in primary tumors with evidence of metastasis and in metastatic lesions, the number of CD271/Sox10-positive cells was relatively increased, suggesting that their frequency is associated with the metastatic potential in human melanoma.

To specifically address this issue, we focused our analysis on 54 primary malignant melanomas of a sentinel lymph node study for which tumor-specific survival data were available (12). Within this cohort, a frequency of CD271/Sox10-positive cells greater than 5% was associated with poor tumor-specific survival ($P = 0.03$; Fig. 5D). Together, these findings support the hypothesis that an elevated frequency of melanoma cells expressing NCSC markers is a prognostic factor for the development of metastasis.

Discussion

In this study we show that human melanoma contains cells that fulfill the definition of cancer stem cells, including the capacity for extensive *in vivo* self-renewal, maintaining long-term tumor growth, and faithfully recapitulating the cellular composition of the patient tumor, from which the cells have been derived. These melanoma stem cells share properties with normal NCSCs, the precursors of melanocytes in the skin. Indeed, human melanoma stem cells express the NCSC markers CD271 and Sox10, and, similar to NCSCs, have the capacity to self-renew and to generate multiple cell types *in vitro* and *in vivo*. CD271-expressing melanoma cells have most recently been shown to exhibit an increased tumor-initiating capacity as compared with CD271-negative cells in fully immunocompromised mice (9). In addition, as we show here, CD271-positive melanoma cells are not only able to initiate tumorigenesis, but invariably regenerate heterogeneous tumors analogous to the parental tumors in patients, even

Downloaded from http://aacrjournals.org/cancerres/article-pdf/71/8/3098/2661525/3098.pdf by guest on 29 April 2025



Primary melanoma stage	*n*	%CD271/Sox10 (± SD)	Median [IQR]
Nonmetastatic	32	4 ± 17	0 [0-1]
Metastatic	22	18 ± 35	1 [0-9.5]
P		0.01	

Stage	% CD271/Sox10 (±SD)			
	n	Tumor tissue	*n*	Cell lines
Primary melanoma	32	4 ± 17	22	6 ± 21
Melanoma metastasis	141	6 ± 18	26	13 ± 30
P		0.04		0.01

Figure 5. The frequency of cells expressing the NCSC markers CD271 and Sox10 in human melanoma correlates with metastatic potential and worse prognosis. A, representative staining of a melanoma cell line, a primary melanoma and a metastasis for CD271 (red) and Sox10 (brown; arrows, insets). Scale bar, 50 μm. B, staining of 54 primary melanomas with known clinical course (32 developed metastases within 5 years, 22 did not) for CD271 and Sox10. The frequency of cells coexpressing CD271 and Sox10 is presented as mean ± SD and median with IQR. C, staining of 32 primary and 141 metastatic melanomas as well as 22 cell lines from primary and 26 from metastatic melanoma lesions for CD271 and Sox10. The frequency of cells coexpressing CD271 and Sox10 is presented as mean ± SD. D, correlation between tumor-specific survival of melanoma patients with the frequency of CD271/Sox10-positive melanoma cells.

after serial retransplantation. Importantly, CD271-positive cells were required for continuous melanoma growth, as long-term passaging and expansion of tumors was dependent on the presence of a CD271-positive cell fraction in the tumor.

The recent debate on whether particular surface markers can be used to distinguish tumorigenic from nontumorigenic melanoma cells in human biopsies (8–11) has pointed out the importance of establishing appropriate methods for cancer cell isolation from solid tumors and for the study of tumorigenic properties *in vivo* (3, 11, 22). Our work shows that an excess of proteolytic trypsin activity during tumor digestion and cell fraction preparation can significantly reduce the percentage of cells positive for a given surface marker in immunolabeling assays. In particular, trypsin treatment substantially lowered the detectability of CD271- and ABCB5-positive cells by specific antibodies as compared with more gentle protocols of tumor digestion, presumably because of proteolytic cleavage of surface epitopes. Our findings conceivably explain the discrepancies between conflicting reports on the nature of melanoma subpopulations with tumor-initiation potential. Specific markers defining tumorigenic cells have been identified in studies avoiding trypsin during melanoma cell fraction preparation (refs. 8, 9; this study), whereas no such markers were identified when trypsin has been included in the tumor digestion protocol (10, 11). Thus, we propose that trypsin treatment of melanoma cells can yield cell fractions false-negative for a given cell surface marker. The resulting contamination of supposedly marker-negative cell fractions by cells actually expressing the marker might explain why in some experimental setups cells positive for CD271 or ABCB5 as well as cells seemingly negative for these markers seemed to be equally tumorigenic and to give rise to tumors reexpressing the markers (10, 11). Moreover, loss of surface epitopes might generally affect the capacity of a tumor cell to associate with the surrounding tissue on transplantation and to initiate tumor formation.

Strikingly, complete phenocopies of parental tumors were never obtained in NSG mice, irrespective of whether bulk tumor cells or isolated cell fractions were used for xenograft experiments. Furthermore, only fully immunocompromised NSG mice provided a host environment permissive for tumor growth by CD271-negative cells, whereas these cells were unable to initiate tumorigenesis in more immunocompetent models. In contrast, CD271-expressing melanoma stem cells were tumorigenic in all mouse models tested, indicating a specific capacity for immune evasion by the stem cell population. The apparent immunoselection of melanoma stem cells in xenografts involves the innate immune system, as NK cell depletion in nude or NOD/SCID mice restored the capacity of CD271-negative cells to form tumors. In agreement with these results, NK and NKT cells have been shown to play a central part during immune surveillance of chemically induced skin tumor in mice (23–25). In addition, there are many lines of evidence supporting the concept of immunoediting also in human tumors, including melanoma (26, 27).

There are a number of mechanisms by which tumor cells may escape or suppress an immune response (28). Melanoma cells might achieve immunogenic tolerance by promoting apoptotic cell death or inactivation of antigen-reactive cells (29) or by inducing an immunosuppressive environment as provided, for instance, by increased levels of immunosuppressive macrophages and neutrophils (30). Interestingly, it has recently been shown that ABCB5-positive melanoma cells have the capacity to inhibit interleukin-2–dependent T-cell

Downloaded from http://aacrjournals.org/cancerres/article-pdf/71/8/3098/2661525/3098.pdf by guest on 29 April 2025

activation and to induce tolerization by regulatory T cells (31). Reduced expression levels of specific tumor antigens, such as Melan-A/MART-1, tyrosinase, and gp-100, might present another mechanism for immune evasion by melanoma cells. Notably, CD271- and ABCB5-positive melanoma cells express low levels of melanoma-associated antigens such as MART-1, supporting the idea that melanoma cells expressing melanoma stem cell markers escape the immune system attack by the host (refs. 9, 29, 31; G. Civenni and L. Sommer, unpublished data). Of note, we identified a subpopulation of CD271-positive melanoma cells that also express ABCB5 (G. Civenni and L. Sommer, unpublished data), although the functional implication of this finding remains to be addressed. All together, these results suggest that in patients, melanoma stem cells might be able to evade or modulate the immune response, allowing these cells to promote tumorigenic growth and to provide resistance to immunotherapy. The hypothesis that these processes are relevant in patients is further supported by our data that only in mice with a certain level of immunocompetence, CD271-positive melanoma cells generated tumors fully phenocopying the original patient melanoma. However, because xenotransplantation models cannot accurately recapitulate the immune response induced by cancer in human patients, the interaction between cancer cell populations and the immune system should be addressed by using syngeneic melanoma mouse models, in which components of the anticancer immune system can be manipulated during tumor initiation and progression.

Our data are consistent with the idea that CD271-positive melanoma cells play a crucial role in tumor formation in human patients. This is further supported by our clinical data obtained with an extensive tissue array of melanoma samples. These show an association between the proportion of CD271/Sox10-positive cells in primary melanoma and metastatic disease as well as poor tumor-specific survival. Hence, high numbers of melanoma stem cells expressing NCSC markers might influence aggressiveness and the metastatic behavior of malignant melanoma. This conceivably reflects intrinsic, NCSC-like features of melanoma stem cells, given that normal NCSCs have the capacity to extensively migrate through embryonic tissue before differentiation into melanocytes and other cell types. In support of this, increased levels of CD271 expression in melanoma have been associated with enhanced invasive potential in culture (32). Interestingly, CD271/Sox10 expression in metastatic primary melanoma was higher than that in metastatic lesions, which could be explained by different patient groups. Whereas all primary melanomas (metastatic versus nonmetastatic) were primary tumors without chemotherapy or vaccination therapy, tissue of the metastases was obtained from patients after adjuvant therapies. Possibly, this therapy might result in a lower prevalence of cells with CD271/Sox10 expression in the metastases. Alternatively, the site of primary metastatic tumor formation might offer a microenvironment more favorable for stem cells than provided by distant metastases. In any case, however, the proportion of CD271/Sox10-positive cells can potentially be used as a predictor of metastases and consequently poor tumor-specific survival. This in turn suggests that monitoring melanoma cells with NCSC-like features in primary melanoma might be of great prognostic relevance.

Several biopsies of primary, mostly nonmetastatic melanoma did not contain CD271/Sox10-positive cells according to our TMA analysis. CD271/Sox10-positive cells might therefore be involved in the formation of metastatic melanoma, whereas less aggressive tumors might originate from other types of melanoma-initiating cells. By extrapolation one could argue that tumor aggressiveness depends on whether the key oncogenic mutation occurred in a normal stem cell or in a more restricted progenitor cell (33). However, although the melanoma stem cells identified in this study display similar marker expression and potential as normal NCSCs in the adult skin (16, 34), melanoma-initiating cells could also arise by dedifferentiation of more mature melanocytic cells (35). Similarly, we cannot exclude that depending on the context or the oncogenotype, CD271/Sox10-melanoma stem cells emerge from other tumor cells, for instance on a process reminiscent of an epithelial-to-mesenchymal transition during metastasis or by epigenetic modification (36, 37). Intriguingly, however, at least in the conditions chosen for this study, CD271 expression was a stable trait of human melanoma-initiating cells, and we did not find any evidence for CD271-positive cells originating from the CD271-negative tumor cell fraction even after prolonged incubation *in vivo*. Moreover, CD271-negative cells did not acquire properties of actual melanoma stem cells, in that they could neither reproduce the cellular heterogeneity of parental tumors nor sustain long-term tumor formation.

In conclusion, the identification of human melanoma stem cells required for continuous tumor growth points to potential culprits of tumor formation in patients. In the future, it might be possible to establish specific treatments that reduce tumorigenesis by elimination of these cells or by targeting "stemness" in melanoma (1). Thus, efforts should be made to develop drugs able to promote differentiation of melanoma stem cells, to selectively kill these cells, or to specifically block their self-renewal and expansion.

Disclosure of Potential Conflict of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank M. Storz, P. Frei, and S. Behnke for assistance and Dr. M. Frank for providing the antibody to ABCB5. We would also like to thank the technical staff of the Central Flow Cytometry Laboratory of the ETH and University of Zurich for their assistance.

Grant Support

This work was supported by the Swiss Cancer League, the Swiss National Science Foundation, the Vontobel Foundation, UBS Wealth Management and the Swiss NCCR "Neural Plasticity and Repair."

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received November 3, 2010; revised January 31, 2011; accepted February 14, 2011; published OnlineFirst March 10, 2011.

Downloaded from http://aacrjournals.org/cancerres/article-pdf/71/8/3098/2661525/3098.pdf by guest on 29 April 2025

References

1. Ward RJ, Dirks PB. Cancer stem cells: at the headwaters of tumor development. Annu Rev Pathol 2007;2:175–89.
2. Cho RW, Clarke MF. Recent advances in cancer stem cells. Curr Opin Genet Dev 2008;18:48–53.
3. Dirks P. Cancer stem cells: Invitation to a second round. Nature 2010;466:40–1.
4. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005;65:9328–37.
5. Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, Cavazzin C, et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 2007;43:935–46.
6. Keshet GI, Goldstein I, Itzhaki O, Cesarkas K, Shenhav L, Yakirevitch A, et al. MDR1 expression identifies human melanoma stem cells. Biochem Biophys Res Commun 2008;368:930–6.
7. Zabierowski SE, Herlyn M. Melanoma stem cells: the dark seed of melanoma. J Clin Oncol 2008;26:2890–4.
8. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, et al. Identification of cells initiating human melanomas. Nature 2008;451:345–9.
9. Boiko AD, Razorenova OV, van de Rijn M, Swetter SM, Johnson DL, Ly DP, et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 2010;466:133–7.
10. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature 2008;456:593–8.
11. Quintana E, Shackleton M, Foster HR, Fullen DR, Sabel MS, Johnson TM, et al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 2010;18:510–23.
12. Mihic-Probst D, Kuster A, Kilgus S, Bode-Lesniewska B, Ingold-Heppner B, Leung C, et al. Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma. Int J Cancer 2007;121:1764–70.
13. Reschke M, Mihic-Probst D, van der Horst EH, Knyazev P, Wild PJ, Hutterer M, et al. HER3 is a determinant for poor prognosis in melanoma. Clin Cancer Res 2008;14:5188–97.
14. Kléber M, Lee HY, Wurdak H, Buchstaller J, Riccomagno MM, Ittner LM, et al. Neural crest stem cell maintenance by combinatorial Wnt and BMP signaling. J Cell Biol 2005;169:309–20.
15. Yoshino H, Ueda T, Kawahata M, Kobayashi K, Ebihara Y, Manabe A, et al. Natural killer cell depletion by anti-asialo GM1 antiserum treatment enhances human hematopoietic stem cell engraftment in NOD/Shi-scid mice. Bone Marrow Transplant 2000;26:1211–6.
16. Wong CE, Paratore C, Dours-Zimmermann MT, Rochat A, Pietri T, Suter U, et al. Neural crest-derived cells with stem cell features can be traced back to multiple lineages in the adult skin. J Cell Biol 2006;175:1005–15.
17. Hoek KS, Schlegel NC, Brafford P, Sucker A, Ugurel S, Kumar R, et al. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res 2006;19: 290–302.
18. Follenzi A, Naldini L. Generation of HIV-1 derived lentiviral vectors. Methods Enzymol 2002;346:454–65.
19. Stemple DL, Anderson DJ. Isolation of a stem cell for neurons and glia from the mammalian neural crest. Cell 1992;71:973–85.
20. Paratore C, Goerich DE, Suter U, Wegner M, Sommer L. Survival and glial fate acquisition of neural crest cells are regulated by an interplay between the transcription factor Sox10 and extrinsic combinatorial signaling. Development 2001;128:3949–61.
21. Held MA, Curley DP, Dankort D, McMahon M, Muthusamy V, Bosenberg MW. Characterization of melanoma cells capable of propagating tumors from a single cell. Cancer Res 2010;70:388–97.
22. Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 2009;138: 822–9.
23. Smyth MJ, Thia KY, Street SE, Cretney E, Trapani JA, Taniguchi M, et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 2000;191:661–8.
24. Smyth MJ, Godfrey DI. NKT cells and tumor immunity–a double-edged sword. Nat Immunol 2000;1:459–60.
25. Smyth MJ, Crowe NY, Godfrey DI. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol 2001;13:459–63.
26. MacKie RM, Reid R, Junor B. Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N Engl J Med 2003;348: 567–8.
27. Sengupta N, MacFie TS, MacDonald TT, Pennington D, Silver AR. Cancer immunoediting and "spontaneous" tumor regression. Pathol Res Pract 2010;206:1–8.
28. Mapara MY, Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 2004;22:1136–51.
29. Schatton T, Frank MH. Antitumor immunity and cancer stem cells. Ann N Y Acad Sci 2009;1176:154–69.
30. De Santo C, Arscott R, Booth S, Karydis I, Jones M, Asher R, et al. Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A. Nat Immunol 2010;11:1039–46.
31. Schatton T, Schütte U, Frank NY, Zhan Q, Hoerning A, Robles SC, et al. Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res 2010;70:697–708.
32. Walch ET, Albino AP, Marchetti D. Correlation of overexpression of the low-affinity p75 neurotrophin receptor with augmented invasion and heparanase production in human malignant melanoma cells. Int J Cancer 1999;82:112–20.
33. Curtis SJ, Sinkevicius KW, Li D, Lau AN, Roach RR, Zamponi R, et al. Primary tumor genotype is an important determinant in identification of lung cancer propagating cells. Cell Stem Cell 2010;7:127–33.
34. Shakhova O, Sommer L. Neural crest-derived stem cells. In: StemBook [Internet]. Cambridge (MA): Harvard Stem Cell Institute; 2010.
35. Real C, Glavieux-Pardanaud C, Le Douarin NM, Dupin E. Clonally cultured differentiated pigment cells can dedifferentiate and generate multipotent progenitors with self-renewing potential. Dev Biol 2006;300:656–69.
36. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704–15.
37. Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A, et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010;141:583–94.

Downloaded from http://aacrjournals.org/cancerres/article-pdf/71/8/3098/2661525/3098.pdf by guest on 29 April 2025